This review article illuminates the role of liquid biopsy in the continuum of care for non-small cell lung cancer (NSCLC). We discuss its current application in advanced-stage NSCLC at the time of diagnosis and at progression. We highlight research showing that concurrent testing of blood and tissue yields faster, more informative, and cheaper answers than the standard stepwise approach. We also describe future applications for liquid biopsy including treatment response monitoring and testing for minimal residual disease. Lastly, we discuss the emerging role of liquid biopsy for screening and early detection.
Keywords: Circulating tumor DNA (ctDNA); Liquid biopsy; Minimal residual disease (MRD); Next-generation sequencing (NGS); Non-small cell lung cancer (NSCLC); Tumor mutational burden (TMB).
Copyright © 2023 Elsevier Inc. All rights reserved.